Business Context and Reporting Period
Aimei Health Technology Co., Ltd. (AFJK), a Cayman Islands-based emerging growth company, filed this Form 8-K on April 17, 2026. The report addresses a compliance issue regarding the timely filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance status rather than financial performance data.
Material Changes and Compliance Status
- Delisting Notice: On April 17, 2026, the Company received a notice from Nasdaq stating it is not in compliance with Listing Rule 5250(c)(1) due to the failure to file its 2025 Annual Report by the March 31, 2026 deadline.
- Current Status: The notice has no immediate effect on the listing or trading of the Company's securities (Ordinary Shares, Rights, and Units) on Nasdaq.
- Previous Action: The Company filed a Notification of Late Filing on Form 12b-25 with the SEC on April 1, 2026.
Outlook, Risks, and Management Commentary
Management states it is working diligently to complete and file the Annual Report and expects to regain compliance, though no specific timing assurances are provided. Under Nasdaq rules, the Company has 60 calendar days from the notice date to either file the report or submit a compliance plan. If a plan is accepted, the Company could receive up to 180 calendar days from the original due date to regain compliance. Failure to regain compliance may result in delisting. The filing includes standard forward-looking statement disclaimers regarding inherent risks and uncertainties.
Investor Verification Checklist
- Verify the current status of the Form 10-K for the fiscal year ended December 31, 2025, on the SEC EDGAR database.
- Monitor the Company's ability to file the Annual Report or submit an acceptable compliance plan within the 60-day window following April 17, 2026.
- Review the attached Press Release (Exhibit 99.1) for any additional details on the delay.
- Check for any subsequent 8-K filings regarding the acceptance of a compliance plan or an appeal to a Nasdaq hearings panel.